Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients with Hypertension

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet

NCT05462535

Hypertension,Essential

COMPLETED

An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet

NCT05450575

Hypertension Dyslipidemia

COMPLETED

An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ

NCT05413057

Hypertension,Essential

RECRUITING

The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.

NCT01828359

Hypertension

COMPLETED PHASE4

A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension

NCT01518998

Hypertension

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After taking Amozatan (AMS, amlodipine / rozanthin combination) in patients with essential hypertension, the percentage of patients who reached the mean systolic target blood pressure was evaluated

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amosartan

amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or rosartan monotherapy
* In patients with stage 2 hypertension (SBP 160-179 mmHg), patients requiring a combination therapy to reach the target blood pressure
* Patients who were changed to amosartan while using other hypertensive agents

Exclusion Criteria

* Patients with hypersensitivity to dihydropyridine derivatives of amosartan
* Women who are pregnant or who may be pregnant and breastfeeding
* Patients with severe hepatic dysfunction
* Patients with severe aortic stenosis
* Patients at risk of shock
* Patients participating in other clinical studies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No